Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
GILD [NASD]
Gilead Sciences Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
IndexS&P 500 P/E36.74 EPS (ttm)1.51 Insider Own0.58% Shs Outstand1.53B Perf Week0.95%
Market Cap84.63B Forward P/E19.13 EPS next Y2.90 Insider Trans2.43% Shs Float1.51B Perf Month9.71%
Income2.87B PEG1.38 EPS next Q0.49 Inst Own99.21% Short Float4.03% Perf Quarter30.69%
Sales9.95B P/S8.50 EPS this Y-7.70% Inst Trans1.76% Short Ratio5.10 Perf Half Y46.39%
Book/sh6.65 P/B8.34 EPS next Y47.21% ROA13.54% Target Price64.54 Perf Year118.08%
Cash/sh1.27 P/C43.56 EPS next 5Y26.66% ROE32.88% 52W Range24.12 - 58.06 Perf YTD51.09%
Dividend- P/FCF28.20 EPS past 5Y14.79% ROI17.09% 52W High-4.44% Beta0.52
Dividend %- Quick Ratio1.13 Sales past 5Y18.06% Gross Margin74.63% 52W Low130.06% ATR1.82
Employees5000 Current Ratio1.55 Sales Q/Q10.92% Oper. Margin42.63% RSI (14)59.37 Volatility3.19% 2.86%
OptionableYes Debt/Eq0.79 EPS Q/Q52.58% Profit Margin28.68% Rel Volume0.90 Prev Close55.93
ShortableYes LT Debt/Eq0.69 EarningsMay 02 AMC Payout0.00% Avg Volume11.93M Price55.48
Recom1.80 SMA203.31% SMA509.80% SMA20040.45% Volume10,762,569 Change-0.80%
17-May-13Reiterated UBS Buy $63 → $67
03-May-13Reiterated Oppenheimer Outperform $59 → $61
03-May-13Reiterated Needham Buy $45 → $62
29-Apr-13Reiterated RBC Capital Mkts Outperform $55 → $62
22-Apr-13Reiterated Maxim Group Buy $48 → $97
17-Apr-13Reiterated Oppenheimer Outperform $50 → $59
16-Apr-13Reiterated Deutsche Bank Buy $48 → $69
15-Apr-13Reiterated Barclays Overweight $42 → $65
09-Apr-13Reiterated RBC Capital Mkts Outperform $50 → $55
25-Mar-13Reiterated Maxim Group Buy $43 → $48
14-Mar-13Reiterated Oppenheimer Outperform $45 → $50
28-Feb-13Reiterated RBC Capital Mkts Outperform $44 → $50
05-Feb-13Reiterated UBS Buy $47 → $48
05-Feb-13Reiterated Stifel Nicolaus Buy $45 → $49
05-Feb-13Reiterated Needham Buy $37.50 → $45
30-Jan-13Reiterated UBS Buy $43.50 → $47
22-Jan-13Reiterated Barclays Overweight $76 → $84
04-Jan-13Resumed Robert W. Baird Outperform $86
18-Dec-12Reiterated UBS Buy $80 → $87
13-Nov-12Reiterated Stifel Nicolaus Buy $80 → $85
23-May-13 06:03PM  Final Glance: Biotechnology companies AP
03:15PM  A Trio of ETFs Sitting on 30% Gains This Year ETF Trends
02:04PM  Amgen Stock Checkup for May at Motley Fool
01:47PM  Midday Glance: Biotechnology companies AP
12:28PM  Cirrus Logic Tumbles On Profit Margin Guidance and 2 Other Hot Stocks to Watch at Wall St. Cheat Sheet
10:46AM  Early Glance: Biotechnology companies AP
22-May-13 06:08PM  Final Glance: Biotechnology companies AP
03:55PM  Gilead's Sofosbuvir under European Review Zacks
02:49PM  Watch This HCV Player at Motley Fool
01:18PM  Buy Bristol-Myers, Says Citi; Stock Jumps 7% at Barrons.com
01:17PM  Midday Glance: Biotechnology companies AP
12:51PM  [video] Best Buy: Buy, Sell or Hold? at CNBC
11:45AM  Hedge Funds Trail S&P 500 by 10 Percentage Points, Goldman Says at Bloomberg
11:03AM  Tiger Cub John Griffin's Top Stock Picks For Q2 at Seeking Alpha
10:51AM  Early Glance: Biotechnology companies AP
10:33AM  Gilead Stock Hits New 52-Week High (GILD) at TheStreet
21-May-13 08:50PM  Final Glance: Biotechnology companies AP
06:29PM  [$$] A Sampling of "High-Conviction" Stocks and Other Names at Barrons.com
04:51PM  Gilead's sofosbuvir gets EMA validation, now under assessment at theflyonthewall.com
04:30PM  InPlay: Gilead Sciences: European Medicines Agency validates Gilead's Marketing Application for sofosbuvir for the treatment of Hepatitis C Briefing.com
04:30PM  European Medicines Agency Validates Gileads Marketing Application for Sofosbuvir for the Treatment of Hepatitis C Business Wire
03:05PM  Roche, Reloaded at Investopedia
02:22PM  Wall Street Transcript Interview with David Ferreiro, Executive Director and Senior Analyst at Oppenheimer & Co. Inc.: Opportunities in Hepatitis C and Genomic Technologies Wall Street Transcript
01:16PM  Midday Glance: Biotechnology companies AP
11:10AM  Cramer: Buy Gilead Sciences, General Mills, Genworth Financial, and These 2 Stocks at Wall St. Cheat Sheet
10:36AM  Early Glance: Biotechnology companies AP
09:10AM  Will Influenza A H7N9 Generate Opportunities For Pharma? at Seeking Alpha
06:00AM  Cramer's Top Stock Picks: SAVE GILD BMY HTA TSLA at TheStreet
20-May-13 06:26PM  Cramer's Watch List Ahead of Big Cancer Conference at CNBC
06:25PM  [video] The War Against Cancer at CNBC
06:05PM  Final Glance: Biotechnology companies AP
04:30PM  3 Upgrades on Friday Worth Noting at Motley Fool
03:00PM  Bayer says lung drug shows promise in prolonged trial at Reuters
01:34PM  Gilead Sciences' Management Presents at the 2013 UBS Global Healthcare Conference (Transcript) Seeking Alpha
01:16PM  Midday Glance: Biotechnology companies AP
01:04PM  5 Stocks Underperforming Today In The Drugs Industry at TheStreet
10:31AM  Early Glance: Biotechnology companies AP
19-May-13 06:30PM  Tackling Cancer: Leukemia's Biggest Current and Upcoming Players at Motley Fool
18-May-13 08:45AM  3 Horrendous Health-Care Stocks This Week at Motley Fool
17-May-13 06:03PM  Final Glance: Biotechnology companies AP
04:49PM  Staples Launches Sports & Art Photo Gallery and 2 More Heavily Traded Stocks to Follow at Wall St. Cheat Sheet
04:05PM  Gilead Sciences to Present at the 2013 UBS Global Healthcare Conference on Monday, May 20 Business Wire
01:32PM  Midday Glance: Biotechnology companies AP
12:22PM  Jim Cramer: Buy Gilead Sciences, Kinder Morgan, and These 3 Solid Stocks Now at Wall St. Cheat Sheet
11:07AM  Bypassing Biotechs and Focusing on the Overlooked Medical Device Space: An Expert Portfolio Manager Discusses His Contrarian Approach to Investing Wall Street Transcript
10:45AM  Analyst Moves: NOC, GM, GILD at Forbes
10:25AM  Early Glance: Biotechnology companies AP
06:20AM  Cramer's Lightning Round - I've Had It With Magnum Hunter (5/16/13) at Seeking Alpha
06:00AM  'Mad Money' Lightning Round: Magnum Hunter Blew It at TheStreet
16-May-13 07:15PM  [$$] AbbVie Is Good Medicine at Barrons.com
06:42PM  Lightning Round: Starbucks, Gilead & More at CNBC
06:03PM  Final Glance: Biotechnology companies AP
03:35PM  Eyeing Business Models and Practices that are Sustainable and Value-Creating in the Biotech and Pharmaceutical Sectors Wall Street Transcript
03:29PM  Gilead Drug For Leukemia Shows Success In Early Trial at Investor's Business Daily
02:09PM  [video] Biotech's Next Big Thing ASCO II at TheStreet
02:09PM  [video] Biotech's Next Big Thing -- ASCO II at TheStreet
01:30PM  Pipeline Progress at Gilead Zacks
01:29PM  Midday Glance: Biotechnology companies AP
11:50AM  Celgene, Gilead lower after new data published at ASCO at theflyonthewall.com
10:35AM  Early Glance: Biotechnology companies AP
15-May-13 07:10PM  Cancer Meeting Highlights the Good and Bad of the Immune System at Motley Fool
07:09PM  With 'Cell Death' Drugs, Bristol-Myers May Win No Matter What at Forbes
06:38PM  InPlay: Gilead Sciences announces resposne data from Phase 2 study of idelalisib for previously untreated chronic lymphocytic leukemia Briefing.com
06:30PM  Gilead Announces Response Data from Phase 2 Study of Idelalisib for Previously Untreated Chronic Lymphocytic Leukemia Business Wire
06:02PM  Final Glance: Biotechnology companies AP
06:00PM  Roche Experimental Leukemia Drug Helps Shrink Tumors at Bloomberg
06:00PM  ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up at TheStreet
06:00PM  ASCO '13 Preview: Gilead's Big Cancer Debut at TheStreet
05:59PM  Experimental Gilead drug effective in early-stage leukemia trial at Reuters
01:26PM  Midday Glance: Biotechnology companies AP
01:03PM  5 Stocks Boosting The Drugs Industry Higher at TheStreet
12:58PM  Cramer: Buy Netflix and US Airways, Buy Gilead Sciences, Buy Ensco at Wall St. Cheat Sheet
12:22PM  ACADIA Prices Public Offering and 2 Other Hot Stocks to Watch at Wall St. Cheat Sheet
10:31AM  Cramer's '4 Horsemen of the Apocalypse' for Shorts CNBC
10:24AM  Early Glance: Biotechnology companies AP
09:58AM  Gilead Reaches New 52-Week High (GILD) at TheStreet
09:31AM  [video] Cramer's '4 Horsemen of the Apocalypse' for Shorts at CNBC
08:21AM  Racing Toward the Next Hepatitis C Drug Approval at Motley Fool
14-May-13 06:02PM  Final Glance: Biotechnology companies AP
06:00PM  Jim Cramer's 5 Investing Sweet Spots at CNBC
04:05PM  Gilead Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15 Business Wire
02:16PM  Should You Buy Stock in Gilead After the Earnings Miss? at Motley Fool
02:10PM  Midday Glance: Biotechnology companies AP
01:04PM  GILEAD SCIENCES INC Financials EDGAR Online Financials
12:24PM  Blue Ridge Capital betting big on a pharma stock at MarketWatch
10:36AM  Early Glance: Biotechnology companies AP
08:58AM  Morning Read: Biotech Under the Microscope at Barrons.com
07:01AM  Stock Market News for May 14, 2013 Zacks
06:13AM  The 8 Biggest Health Problems Americans Face at Motley Fool
06:10AM  [$$] Biotech Fund: Many Healthy Returns at Barrons.com
13-May-13 06:04PM  FDA Prioritizes New Hepatitis C Drug at Motley Fool
06:02PM  Final Glance: Biotechnology companies AP
05:00PM  Gilead Sciences Inc (GILD): Today's Featured Health Care Winner at TheStreet
04:37PM  This Big Hedge Fund Is Bullish On Big Companies; Should You Be? at Seeking Alpha
04:10PM  [video] Solar Stocks Hit 52-Week Highs at CNBC
01:18PM  Midday Glance: Biotechnology companies AP
01:04PM  Midday Movers: GILD, BSX, AES & More at CNBC
10:23AM  Early Glance: Biotechnology companies AP
07:35AM  Stock Market News for May 13, 2013 Zacks
06:38AM  GILEAD SCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or EDGAR Online
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. The company also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, it provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. Further, it has product candidates in various stages for the treatment of cardiovascular diseases, respiratory diseases, and oncology diseases/inflammation. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, GSK, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alton Gregg HEVP, Corp & Med AffairsMay 01Option Exercise16.4026,000426,27093,938May 03 05:12 PM
MARTIN JOHN CChairman and CEOMay 01Option Exercise7.63282,2422,154,2124,339,363May 03 06:15 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Sale50.2030,0001,506,12363,938May 03 05:12 PM
MARTIN JOHN CChairman and CEOMay 01Sale50.17282,24214,160,9564,057,121May 03 06:15 PM
Washington Robin LSVP, CFOApr 11Sale50.2096848,59427,130Apr 15 02:42 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Option Exercise16.4026,000426,27097,938Apr 03 06:16 PM
Washington Robin LSVP, CFOApr 01Option Exercise26.5713,000345,41538,098Apr 03 06:17 PM
MARTIN JOHN CChairman and CEOApr 01Option Exercise7.63282,2422,154,2124,339,363Apr 03 04:26 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale48.3730,0001,451,08067,938Apr 03 06:16 PM
Washington Robin LSVP, CFOApr 01Sale48.3313,000628,32928,098Apr 03 06:17 PM
MARTIN JOHN CChairman and CEOApr 01Sale48.30282,24213,633,5344,057,121Apr 03 04:26 PM
Washington Robin LSVP, CFOMar 27Option Exercise27.0745,0001,218,15073,098Mar 29 12:54 PM
Washington Robin LSVP, CFOMar 27Sale47.0745,0002,118,15028,098Mar 29 12:54 PM
Washington Robin LSVP, CFOMar 14Sale45.854,304197,32128,098Mar 18 07:43 PM
Washington Robin LSVP, CFOMar 05Option Exercise24.3045,0001,093,27568,794Mar 06 06:23 PM
Washington Robin LSVP, CFOMar 05Sale44.4145,0001,998,45023,794Mar 06 06:23 PM
Washington Robin LSVP, CFOMar 04Option Exercise23.689,800232,02433,594Mar 06 06:23 PM
Washington Robin LSVP, CFOMar 04Sale43.689,800428,04823,794Mar 06 06:23 PM
MARTIN JOHN CChairman and CEOMar 01Option Exercise7.63282,2422,154,2124,288,674Mar 05 05:13 PM
Alton Gregg HEVP, Corp & Med AffairsMar 01Option Exercise16.4026,000426,27088,548Mar 05 04:07 PM
MARTIN JOHN CChairman and CEOMar 01Sale43.14282,24212,176,0634,006,432Mar 05 05:13 PM
Alton Gregg HEVP, Corp & Med AffairsMar 01Sale43.0830,0001,292,44258,548Mar 05 04:07 PM
WOLD OLSEN PERDirectorFeb 28Buy43.0510,000430,49369,458Mar 04 03:57 PM
MARTIN JOHN CChairman and CEOFeb 01Option Exercise7.63282,2422,154,2124,287,706Feb 05 04:47 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 01Option Exercise15.5926,000405,29191,580Feb 05 04:49 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 01Sale40.4230,0001,212,52061,580Feb 05 04:49 PM
MARTIN JOHN CChairman and CEOFeb 01Sale40.43282,24211,410,4774,005,464Feb 05 04:47 PM
Washington Robin LSVP, CFOJan 28Option Exercise19.0911,550220,43234,376Jan 30 01:29 PM
Washington Robin LSVP, CFOJan 28Sale39.4811,550456,02422,826Jan 30 01:29 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Option Exercise30.18113,0003,410,705147,790Jan 04 03:49 PM
MARTIN JOHN CChairman and CEOJan 02Option Exercise15.27141,1212,154,2122,143,853Jan 04 03:49 PM
MARTIN JOHN CChairman and CEOJan 02Sale74.46141,12110,508,4722,002,732Jan 04 03:49 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Sale74.63115,0008,582,71132,790Jan 04 03:49 PM
MARTIN JOHN CChairman and CEODec 10Option Exercise15.6312,794199,9542,002,732Dec 12 03:09 PM
MARTIN JOHN CChairman and CEODec 03Option Exercise8.94145,5001,301,1342,135,438Dec 05 06:30 PM
Alton Gregg HEVP, Corp & Med AffairsDec 03Option Exercise29.0121,000609,10556,790Dec 05 06:30 PM
Alton Gregg HEVP, Corp & Med AffairsDec 03Sale75.1022,0001,652,24134,790Dec 05 06:30 PM
MARTIN JOHN CChairman and CEODec 03Sale75.01145,50010,914,5931,989,938Dec 05 06:30 PM
MOORE NICHOLAS GDirectorNov 30Option Exercise28.6865,0001,863,87572,309Dec 04 04:51 PM
MOORE NICHOLAS GDirectorNov 30Sale74.9665,0004,872,5507,309Dec 04 04:51 PM
DENNY JAMES MDirectorNov 28Option Exercise23.3864,0001,496,092301,158Nov 30 01:53 PM
DENNY JAMES MDirectorNov 28Sale73.9120,0001,478,224281,158Nov 30 01:53 PM
Washington Robin LSVP, CFONov 12Option Exercise53.2427,9751,489,48033,913Nov 14 06:48 PM
Washington Robin LSVP, CFONov 12Option Exercise53.2427,9751,489,48033,913Nov 14 06:48 PM
Washington Robin LSVP, CFONov 12Option Exercise53.2427,9751,489,48033,913Nov 14 06:48 PM
Washington Robin LSVP, CFONov 12Option Exercise53.2427,9751,489,48033,913Nov 14 06:48 PM
Washington Robin LSVP, CFONov 12Sale73.1127,9752,045,31111,413Nov 14 06:48 PM
Washington Robin LSVP, CFONov 12Sale73.1127,9752,045,31111,413Nov 14 06:48 PM
Washington Robin LSVP, CFONov 12Sale73.1127,9752,045,31111,413Nov 14 06:48 PM
Washington Robin LSVP, CFONov 12Sale73.1127,9752,045,31111,413Nov 14 06:48 PM
Washington Robin LSVP, CFONov 07Option Exercise54.142,500135,35015,512Nov 09 05:16 PM
Washington Robin LSVP, CFONov 07Sale66.304,099271,76511,413Nov 09 05:16 PM
Washington Robin LSVP, CFONov 05Option Exercise0.003,000014,413Nov 07 06:18 PM
MILLIGAN JOHN FPresident and COONov 02Option Exercise17.5070,0001,224,825340,187Nov 06 03:31 PM
MILLIGAN JOHN FPresident and COONov 02Sale67.0170,0004,690,672270,187Nov 06 03:31 PM
MARTIN JOHN CChairman and CEONov 01Option Exercise8.94145,4501,300,6872,135,388Nov 05 06:22 PM
Alton Gregg HEVP, Corp & Med AffairsNov 01Option Exercise29.0121,000609,10557,790Nov 05 08:25 PM
Metza KristenSVP, Human ResourcesNov 01Option Exercise42.8630,0001,285,82055,305Nov 05 08:26 PM
Whitley Richard JamesDirectorNov 01Sale67.817,226490,0063,632Nov 05 08:26 PM
Metza KristenSVP, Human ResourcesNov 01Sale67.7230,0002,031,66625,305Nov 05 08:26 PM
Alton Gregg HEVP, Corp & Med AffairsNov 01Sale67.8022,0001,491,59835,790Nov 05 08:25 PM
MARTIN JOHN CChairman and CEONov 01Sale67.70145,4509,847,5901,989,938Nov 05 06:22 PM
Washington Robin LSVP, CFOOct 31Option Exercise48.392,925141,55413,213Nov 02 02:38 PM
Washington Robin LSVP, CFOOct 31Sale67.632,925197,81611,413Nov 02 02:38 PM
MILLIGAN JOHN FPresident and COOOct 29Option Exercise8.9411,18099,977270,187Oct 31 12:46 PM
DAVIGNON ETIENNEDirectorOct 26Sale67.2420,0001,344,850582,934Oct 30 07:35 PM
Washington Robin LSVP, CFOOct 24Option Exercise47.2062529,50012,038Oct 26 05:44 PM
Washington Robin LSVP, CFOOct 24Sale68.4562542,78111,413Oct 26 05:44 PM
Washington Robin LSVP, CFOOct 22Option Exercise40.387,650308,93217,188Oct 24 04:10 PM
Washington Robin LSVP, CFOOct 22Sale66.167,650506,13411,413Oct 24 04:10 PM
MILLIGAN JOHN FPresident and COOOct 03Option Exercise17.5070,0001,224,825329,007Oct 05 01:00 PM
MILLIGAN JOHN FPresident and COOOct 03Sale69.8570,0004,889,241259,007Oct 05 01:00 PM
Washington Robin LSVP, CFOOct 02Option Exercise47.3314,750698,06020,163Oct 04 03:29 PM
Washington Robin LSVP, CFOOct 02Sale68.6214,7501,012,19111,413Oct 04 03:29 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise29.0121,000609,10558,790Oct 03 12:46 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise8.94145,4501,300,6872,135,388Oct 03 12:46 PM
MARTIN JOHN CChairman and CEOOct 01Sale67.53145,4509,822,6321,989,938Oct 03 12:46 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale67.6622,0001,488,57936,790Oct 03 12:46 PM
Washington Robin LSVP, CFOSep 18Option Exercise49.814,500224,14515,913Sep 19 07:34 PM
Washington Robin LSVP, CFOSep 18Sale67.254,500302,62511,413Sep 19 07:34 PM
Washington Robin LSVP, CFOSep 17Option Exercise52.3857,2502,999,01053,913Sep 19 07:34 PM
Washington Robin LSVP, CFOSep 17Sale64.8357,2503,711,34611,413Sep 19 07:34 PM
Metza KristenSVP, Human ResourcesSep 13Option Exercise41.4675,0003,109,65062,805Sep 17 06:21 PM
Metza KristenSVP, Human ResourcesSep 13Sale59.9590,0005,395,50025,305Sep 17 06:21 PM
Washington Robin LSVP, CFOSep 10Option Exercise49.819,000448,29020,413Sep 11 06:32 PM
Washington Robin LSVP, CFOSep 10Sale59.789,000538,02011,413Sep 11 06:32 PM
Alton Gregg HEVP, Corp & Med AffairsSep 04Option Exercise29.0121,000609,10559,790Sep 06 06:40 PM
MARTIN JOHN CChairman and CEOSep 04Option Exercise8.94145,4501,300,6872,135,388Sep 06 08:33 PM
MILLIGAN JOHN FPresident and COOSep 04Option Exercise17.50140,0002,449,650399,007Sep 06 08:33 PM
MILLIGAN JOHN FPresident and COOSep 04Sale57.41140,0008,037,694259,007Sep 06 08:33 PM
MARTIN JOHN CChairman and CEOSep 04Sale57.68145,4508,390,0131,989,938Sep 06 08:33 PM
Alton Gregg HEVP, Corp & Med AffairsSep 04Sale57.5022,0001,265,06237,790Sep 06 06:40 PM
Metza KristenSVP, Human ResourcesSep 01Option Exercise47.2015,000708,00040,305Sep 17 06:21 PM
Washington Robin LSVP, CFOAug 30Sale57.483,466199,23911,413Sep 04 01:01 PM
MOORE GORDON EARLEDirectorAug 14Option Exercise13.85252,0003,489,3001,063,839Aug 16 04:32 PM
Washington Robin LSVP, CFOAug 02Option Exercise47.3329,5001,396,12032,379Aug 03 04:53 PM
Alton Gregg HEVP, Corp & Med AffairsAug 02Option Exercise24.2160,0001,452,56170,161Aug 03 06:01 PM
Washington Robin LSVP, CFOAug 02Sale57.7329,5001,703,02614,879Aug 03 04:53 PM
Alton Gregg HEVP, Corp & Med AffairsAug 02Sale57.9560,0003,476,85038,790Aug 03 06:01 PM
Metza KristenSVP, Human ResourcesAug 01Option Exercise40.5130,0001,215,30043,305Aug 03 04:31 PM
open in yahoo | open in reuters | open in google